| __timestamp | Geron Corporation | Mesoblast Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 8901000 | 25434000 |
| Thursday, January 1, 2015 | 9574000 | 23783000 |
| Friday, January 1, 2016 | 14695000 | 29763000 |
| Sunday, January 1, 2017 | 8437000 | 12065000 |
| Monday, January 1, 2018 | 12723000 | 5508000 |
| Tuesday, January 1, 2019 | 51272000 | 75173000 |
| Wednesday, January 1, 2020 | 50052000 | 81497000 |
| Friday, January 1, 2021 | 783000 | 85731000 |
| Saturday, January 1, 2022 | 868000 | 63572000 |
| Sunday, January 1, 2023 | 123740000 | 54922000 |
| Monday, January 1, 2024 | 41070000 |
Unleashing insights
In the ever-evolving biotech industry, understanding cost structures is crucial for investors and stakeholders. This analysis compares the cost of revenue for Mesoblast Limited and Geron Corporation from 2014 to 2023. Mesoblast consistently outpaced Geron in cost of revenue, peaking in 2021 with a staggering 85.7 million, while Geron hit its highest in 2023 at 123.7 million. Notably, Mesoblast's costs were more than double Geron's in 2019 and 2020, highlighting its aggressive growth strategy. However, Geron's dramatic increase in 2023 suggests a significant shift in its operational dynamics. Missing data for 2024 indicates potential reporting delays or strategic changes. This decade-long comparison underscores the dynamic nature of biotech financials, offering insights into each company's operational focus and market positioning.
Zoetis Inc. vs Mesoblast Limited: Efficiency in Cost of Revenue Explored
Regeneron Pharmaceuticals, Inc. vs Mesoblast Limited: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down GSK plc and Mesoblast Limited's Expenses
Takeda Pharmaceutical Company Limited vs Geron Corporation: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Intra-Cellular Therapies, Inc. vs Geron Corporation
Cost of Revenue Comparison: Dr. Reddy's Laboratories Limited vs Mesoblast Limited
Walgreens Boots Alliance, Inc. vs Geron Corporation: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Cytokinetics, Incorporated and Mesoblast Limited
Analyzing Cost of Revenue: ACADIA Pharmaceuticals Inc. and Mesoblast Limited
Vericel Corporation vs Geron Corporation: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Mesoblast Limited and Taro Pharmaceutical Industries Ltd.
Cost of Revenue Comparison: Geron Corporation vs Travere Therapeutics, Inc.